Drug Information

Drug General Information
Drug ID
D01XEQ
Former ID
DCL000945
Drug Name
R348
Indication Psoriasis [ICD9: 696; ICD10:L40] Terminated [537117]
Company
Rigel Pharmaceuticals
Target and Pathway
Target(s) Tyrosine-protein kinase JAK3 Target Info Inhibitor [537117]
KEGG Pathway Chemokine signaling pathway
PI3K-Akt signaling pathway
Signaling pathways regulating pluripotency of stem cells
Jak-STAT signaling pathway
Measles
HTLV-I infection
Epstein-Barr virus infection
Viral carcinogenesis
Primary immunodeficiency
PANTHER Pathway Interleukin signaling pathway
JAK/STAT signaling pathway
PDGF signaling pathway
Pathway Interaction Database IL4-mediated signaling events
CD40/CD40L signaling
Signaling events mediated by TCPTP
SHP2 signaling
IL2-mediated signaling events
IL2 signaling events mediated by PI3K
IL2 signaling events mediated by STAT5
Reactome GPVI-mediated activation cascade
Interleukin-7 signaling
G beta:gamma signalling through PI3Kgamma
Interleukin-2 signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways IL-2 Signaling Pathway
IL-4 Signaling Pathway
Interleukin-2 signaling
Interleukin-7 signaling
Oncostatin M Signaling Pathway
IL-9 Signaling Pathway
IL-7 Signaling Pathway
Interleukin-3, 5 and GM-CSF signaling
References
Ref 537117Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
Ref 537117Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.